Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shanghai Haohai Biological Technology Co., Ltd.*

上海昊海生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6826)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made by Shanghai Haohai Biological Technology Co., Ltd.* (the "**Company**") pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

References are made to the announcements of the Company dated 7 May 2025, 16 September 2025 and 23 December 2025, respectively, in relation to the filing of an investigation and the imposition of administrative penalties by the China Securities Regulatory Commission against Mr. Jiang Wei (蒋偉), one of controlling shareholders and de facto controllers of the Company, for his acts of insider trading.

Set out below is the "Shanghai Haohai Biological Technology Co., Ltd.* Announcement on the Receipt of the 'Decision on Release on Bail Pending Trial' by One of the Company's Controlling Shareholders and De Facto Controllers for Matters Unrelated to the Company" published by the Company on the website of the Shanghai Stock Exchange, for reference only.

By order of the Board
Shanghai Haohai Biological Technology Co., Ltd.*
Chairman
Hou Yongtai

Shanghai, the PRC, 30 April 2026

As at the date of this announcement, the executive directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Ms. Chen Yiyi and Mr. Tang Minjie; the non-executive directors of the Company are Ms. You Jie, Mr. Huang Ming and Mr.Wei Changzheng; and the independent non-executive directors of the Company are Mr. Shen Hongbo, Mr. Jiang Zhihong, Mr. Su Zhi and Mr. Yang Yushe.

* *For identification purpose only*

Stock code: 688366 Stock abbreviation: HAOHAI BIOTEC Announcement No.: 2026 -015

Shanghai Haohai Biological Technology Co., Ltd.* Announcement on the Receipt of the "Decision on Release on Bail Pending Trial" by One of the Company's Controlling Shareholders and De Facto Controllers for Matters Unrelated to the Company

The board of directors and all directors of the Company warrant that the content of this announcement does not contain any false records, misleading statements or material omissions, and accept responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

Shanghai Haohai Biological Technology Co., Ltd.* (hereinafter referred to as the "Company") recently was notified by Mr. Jiang Wei, one of controlling shareholders and de facto controllers, that due to the need for the investigation of Mr. Jiang Wei's suspected insider trading case, the Shanghai Municipal Public Security Bureau issued the "Decision on Release on Bail Pending Trial", deciding to release Mr. Jiang Wei on bail, starting from 29 April 2026.

Previously, Mr. Jiang Wei received the Administrative Penalty Decision (2025 No. 151) issued by the China Securities Regulatory Commission in December 2025 for his acts of insider trading. Details are set out in the announcement dated 24 December 2025 published on the website of the Shanghai Stock Exchange (www.sse.com.cn) under the title "Shanghai Haohai Biological Technology Co., Ltd. Announcement on the Receipt of an Administrative Penalty Notice by One of the Company's Controlling Shareholders and De Facto Controllers for Matters Unrelated to the Company" (Announcement No.: 2025-052).

The aforementioned matters are unrelated to the Company. Mr. Jiang Wei does not hold any position as a director, senior executive or any other position in the Company,

and the matter will not have any material impact on the day-to-day operation of the Company. As of the date of this announcement, the Company's production and operation activities are proceeding in an orderly manner as usual. The Company will continue to pay attention to the progress of the above-mentioned matters and fulfill the obligation of information disclosure in a timely manner in accordance with the provisions and requirements of relevant laws and regulations. Information about the Company shall be subject to the announcements published by the Company on the designated information disclosure media and the website of the Shanghai Stock Exchange (www.sse.com.cn). Investors are advised to pay attention to investment risks.

The announcement is hereby made.

The board of directors of Shanghai Haohai Biological Technology Co., Ltd.*

1 May 2026